Roche's checkpoint inhibitor Tecentriq is facing tough competition in the bladder cancer market after falling short in a key clinical trial. Now the company plans to test the drug in combination with Tesaro's PARP inhibitor Zejula.Original Article
In wake of Tecentriq bladder cancer bust and lost market share, Roche tries Tesaro combo
